MEDSOURCE
Taking Relationships as Seriously as Science

Corporate Office
16902 El Camino Real
Houston, TX 77058
Phone 281.286.2003
Fax 281.488.1848

North Carolina Regional Office
6736 Falls of Neuse Rd., Suite 100
Raleigh, NC 27615
Phone 919.792.3740
Fax 919.847.3215

08 August 2012

Patrick McLaughlin
Executive Director
Anaheim Clinical Trial
1085 North Harbor Blvd.
Anaheim, CA 92801

RE: Protocol CBYM338X2106 – Site 1002

Dear Mr. McLaughlin,

This letter is to acknowledge the outstanding efforts of the following study staff for the above referenced Novartis study: Angela Aviles, Phase 1 Clinical Operations, QA Liaison, Rennette Valencia, Clinical Research Coordinator, Michael Gallardo, Clinical Research Coordinator and Sharda Vorda, Study Pharmacist.

Through the contributions of the ACT study team, study enrollment was promptly completed and the number of randomized subjects exceeded the original allotment. I would like to thank the team for their time and efforts, especially in the following areas:

- Source documentation is very well organized and complete.
- EDC data entry is prompt and queries are resolved in a timely manner.
- Suggestions to improve study and EDC processes are well received and systematically implemented.
- Communication is open with Novartis and with me.
- Team approach and unparalleled work ethic.

While monitoring at ACT, it is evident that the entire team takes great pride in their work and strives to provide the highest quality data for the client. I also very much appreciate the hospitality at ACT and for Angela always being so accommodating. I can always count on Angela to find a place for me to work even if all the monitoring rooms are booked. The ACT team truly goes the extra mile to make my job easier. Please extend my sincere gratitude to Angela, Rennette, Michael, Sharda and the entire ACT study team for their important contributions to the program.

Warm regards,

Tammy Yi, CCRA
Sr. Clinical Research Associate Consultant
MedSource

cc: Peter Winkle, MD, Principal Investigator
Angela Aviles, Phase 1 Clinical Operations, QA Liaison
Takami Saji, Novartis Clinical Trial Leader
Bill Kovacs, MedSource Director of Clinical Operations